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Abstract
CD4+ T lymphocytes play an important role in CD8+ T cell–
mediated responses against tumors. Considering that f20%
of melanomas express MHC class II, it is plausible that
concomitant presentation by MHC class I and class II shapes
positive (helper T cells) or negative (regulatory T cells)
antitumor responses. Interestingly, gp100, a melanoma anti-
gen, can be presented by both MHC class I and class II when
expressed endogenously, suggesting that it can reach endo-
somal/MHC class II compartments (MIIC). Here, we showed
that gp100 putative NH2-terminal signal sequence and the
last 70 residues in COOH terminus are essential for MIIC
localization and MHC class II presentation. Confocal micros-
copy analyses confirmed that gp100 was localized in LAMP-1+/
HLA-DR+ endosomal/MIIC. Gp100 targeting sequences were
characterized by deleting different sections in the COOH
terminus (last 70 residues). Transfection in 293T cells,
expressing MHC class I and class II molecules, revealed
that specific deletions in COOH terminus resulted in
decreased MHC class II presentation, without effects on class
I presentation, suggesting a role in MIIC trafficking for these
deleted sections. Then, we used these gp100 targeting
sequences to mobilize green fluorescent protein to endosomal
compartments and to allow MHC class II and class I
presentation of minimal endogenous epitopes. We conclude
that these specific sequences are MIIC-targeting motifs, which
could be included in expression cassettes for endogenously
expressed tumor or viral antigens for MHC class II and class I
presentation and optimize in vivo T-cell responses or as an
in vitro tool for characterization of new MHC class II epitopes.
(Cancer Res 2006; 66(4): 2423-32)
Introduction
Cancer immunotherapy strategies targeting tumor antigens were
mainly developed by eliciting CD8+ CTLs. Over the past decade,
growing evidence has emerged from animal studies (1–3) and
clinical trials (4, 5), indicating that CD4+ helper T lymphocytes play
an important role in initiating and maintaining immune responses
against cancer (6, 7) by expanding effective and memory CD8+
T cells (8, 9). Thus, optimal antitumor immunity might require the
participation of both CD4+ and CD8+ T lymphocytes to generate a
strong and durable response against cancer cells (10, 11). However,
a subset of CD4+ T cells, defined as regulatory T lymphocytes (Treg)
and representing 1% to 2% of the total CD4+ T-cell population (12),
may also play a significant role in human cancer considering their
cognate immunoregulatory functions (13, 14). Treg have suppressive
activities on effective CD8+ (15, 16) and CD4+ (17, 18) T-cell
functions, suggesting that MHC class II–mediated antigen
presentation can potentially be either positive or detrimental in
antitumor immunity.
Considering that f20% to 25% of melanomas naturally express
MHC class II molecules during the process of malignant trans-
formation (19), and perhaps >50% during inflammation and
metastases formation (20, 21), it is plausible that concomitant
antigenic presentation by MHC class I and class II shapes
antitumor responses mediating both positive and negative
mechanisms. Thus, activation of tumor-specific CD8+ and CD4+
T cells may occur at the tumor site. This illustrates the importance
of better defining MHC class II antigenic presentation from
endogenously expressed proteins.
Interestingly, gp100, a melanoma/melanocyte-shared antigen, can
be presented by both MHC class I and class II molecules when
expressed endogenously by melanoma and nonmelanoma cells.
This implies that gp100 can reach endosomal/MHC class II compart-
ments (MIIC) for antigenprocessing and presentation byMHCclass II.
Normally, CD4+ T cells recognize exogenous proteins, which are
ingested by antigen-presenting cells (APC) and get degraded into
peptides which can be coupled with MHC class II molecules in MIIC,
which are lysosome-related organelles (22). These peptide/MHC
class II complexes then migrate to the cell surface. Interestingly,
an endogenous protein can sometimes reach endosomal/MIIC to
be processed similarly to an exogenous protein for MHC class II–
mediatedpresentation. However, endosomal/MIIC internal trafficking
leading to MHC class II presentation remains poorly understood.
We previously generated a CD4+ T-cell clone specific to gp100 by
using retrovirally transduced dendritic cells (23), indicating
plausible MHC class II presentation. We also showed that this
gp100-specific CD4+ T-cell clone could recognize melanoma cell
lines (24), which evoked potential targeting sequences in gp100 for
MHC class II–mediated presentation.
In the current work, we prepared different deletions in the gp100
sequence to assess MHC class I and class II–mediated presentation
and to evaluate endosomal protein localization, with the aim of
finding sequences, within gp100, involved in these processes. We
first confirmed gp100 presentation by MHC class II molecules in
gp100-transfected 293T cells and its endosomal mobilization. Our
data show that both the COOH-terminal (last 70 residues) and
putative NH2-terminal signal sequences are essential for MHC class
II–mediated presentation of endogenous gp100 and other antigens.
Our results also suggest that gp100 may transit to the cell surface to
be internalized in endosomal/MIIC.
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Research Article
A better understanding of the MHC class II presentation of
endogenous antigens may help us to optimize the immune
response directed to gp100 or other tumor antigens in cancer
immunotherapy.
Materials and Methods
Media and cell culture. Complete medium consisted of AIM-V
medium (Invitrogen, Carlsbad, CA) supplemented with 5% human AB
serum (heat-inactivated; Gemini Bio-Products, Calabasas, CA), 2 mmol/L
L-glutamine, 100 units/mL penicillin/streptomycin and 10 Ag/mL genta-
micin (all from Invitrogen). A gp100-specific CD4+ T-cell clone, HLA-
DRh1*0701 restricted (23), and a CD8+ T-cell clone, HLA-A*0201 restricted
(25), were cultured as previously described in complete medium
supplemented with 300 IU/mL recombinant human interleukin (IL)-2
(Chiron, Emeryville, CA).
CD40-stimulated B lymphocytes (CD40-B) were cultured as previously
described (26) in Iscove’s modified Dulbecco’s medium [Invitrogen and
Wisent (St. Bruno, Quebec, Canada)] supplemented with 10% human serum
(heat inactivated, prepared from normal donors), 2 mmol/L L-glutamine,
100 units/mL penicillin/streptomycin, 10 Ag/mL gentamicin, 500 ng/mL of a
soluble trimeric CD40L (Immunex Corporation, Seattle, WA), and 500 units/
mL recombinant human IL-4 (Peprotech, Rocky Hill, NJ).
HEK-293T cells expressing HLA-DRh1*0701 or DRh1*0401, kindly
provided by Dr. Paul F. Robbins and Dr. Suzanne L. Topalian [National
Cancer Institute (NCI)/NIH, Bethesda, MD], and HEK-293T cells expressing
HLA-A*0201 were cultured in RPMI 1640 (Invitrogen and Wisent)
supplemented with 10% heat-inactivated fetal bovine serum (FBS;
Invitrogen and Wisent), 2 mmol/L L-glutamine, 100 units/mL penicillin/
streptomycin, and 10 Ag/mL gentamicin.
The melanoma cell line MelFB, which was immunoselected for the
absence of gp100 and MART-1, was transducted by retroviral vectors
encoding gp100 or green fluorescent protein (GFP) as previously described
(23). Melanoma cell lines 1087mel, 624.38mel, 624.38mel-CIITA, 1088mel,
1102mel, 1300mel, 397mel, 553mel, and SK23mel were established at the
Surgery Branch (NCI/NIH). Breast tumor cell lines MCF-7 and MDA231
were obtained from the American Type Culture Collection (ATCC;
Manassas, VA). All tumor cell lines were cultured in RPMI 1640
supplemented with 10% heat-inactivated FBS, 2 mmol/L L-glutamine, 100
units/mL penicillin/streptomycin, and 10 Ag/mL gentamicin.
Gp100 mutants and other plasmids. Plasmids encoding HLA-A*0201
and A*0101 (pcDNA-A2 and CLNCx-A1, respectively), kindly supplied by
Dr. Paul F. Robbins, were cloned from HLA-typed patients at the NIH.
Plasmid encoding gp100 (pcDNA-gp100) also was gifted by Dr. Paul F.
Robbins (NCI/NIH).
Plasmids encoding the different versions of gp100, deleted in the COOH
terminus or NH2 terminus (presented in Fig. 3A, left), were prepared by PCR
from the wild-type sequence, cloned in pcDNA3.1, and their sequences were
confirmed by sequencing. PcDNA-gp100DTM was internally deleted from
residues 594 to 615, which corresponded to the transmembrane domain,
and pcDNA-gp100 DLL was deleted from residues 650 to the end, which
corresponded to a putative dileucine motif. These latter two constructs
were prepared by Dr. Paul F. Robbins at the Surgery Branch (NCI/NIH).
PcDNA-gp100TM was deleted from residue 615 to the end and pcDNA-
gp100NoTM from residue 594 to the end. PcDNA-gp100DSS was deleted
from residues 1 to 20, which corresponded to the putative NH2-terminal
signal sequence. PcDNA-gp100DYV was deleted from residues 616 to 627,
which corresponded to a sequence including a tyrosine residue. In pcDNA-
gp100CD8, the gp100 transmembrane domain (residues 594-615) was
exchanged with the CD8 transmembrane domain (residues 183-204 of CD8
sequence). PcDNA-gp100DYVCD8 was similar to pcDNA-gp100CD8 but
residues 610 to 627 were also removed.
In the construct pcDNA-gp100/GFP (presented in Fig. 6A), the entire
GFP sequence, from which the first methionine was changed for a valine,
was cloned between the putative NH2-terminal signal sequence (residues
1-20) and the last 70 residues from gp100 (residue 594 to the end). In
pcDNA-gp/GFP+epit (presented in Fig. 6B), residues 150 to 225 from gp100,
which corresponded to minimal MHC class II and class I epitopes, were
inserted after the GFP sequence.
Cell transfection and APC pulsing. The day before transfection, cells
were plated at 5  105 per well in six-well plates to get 50% to 90%
confluence on the day of transfection. The cells were transiently transfected
employing Lipofectamine Plus Reagent (Invitrogen) according to the
instructions of the manufacturer. Transfected cells were cultured for
an additional 24 hours. We routinely reached between 30% and 50%
transfection efficiency.
In some experiments, MelFB and CD40-B cells were electroporated in a
nucleofection system (Amaxa Biosystems, Gaithersburg, MD) according to
the instructions of the manufacturer.
The HLA-DRh1*0701-binding peptide gp100170-190 (23) and the HLA-
DRh1*0701 control binding peptide Ign188-202 (27) were synthesized at the
Surgery Branch (NCI/NIH). Recombinant gp100 protein was prepared as
previously described (28). Recombinant NY-ESO-1 protein (29), another
tumor antigen, served as a negative control. Peptide or protein pulsing of
CD40-B cells (1  105) was carried out in B-cell culture medium for 16 hours
in 96-well flat-bottomed plates.
T-cell assays. Gp100-specific T-cell clones were analyzed for their capacity
to recognize target cells, such as gp100-transfected 293T cells, melanoma cell
lines, or CD40-B pulsed with synthetic peptides or recombinant proteins.
Target cells (1  105) were cocultured with either a specific CD4+ T-cell clone
(2  104) or a specific CD8+ T-cell clone (1  105) in 200 AL of complete
medium in 96-well flat-bottomed plates. Supernatants were harvested after
20-hour incubation and human interferon-g (IFN-g) was assayed by ELISA
with coupled antibodies (Endogen, Woburn, MA).
In some experiments, chloroquine (Sigma, St. Louis, MO) was added on
target cells at 100 Amol/L for 4 hours. Cells were washed once and fixed
with 0.5% of formaldehyde for 5 minutes. They were then extensively
washed thrice and cocultured with T cells in 200 AL of complete medium in
96-well flat-bottomed plates.
Western blotting. Protein extracts were prepared from gp100-
transfected 293T cells at 4jC, for 20 minutes, in lysis buffer [20 mmol/L
Tris-HCl (pH 8), 137 mmol/L NaCl, 10% glycerol, 1% Triton X-100,
1 mmol/L Na3VO4, and 2 mmol/L EDTA] containing protease inhibitors
(1 mmol/L phenylmethylsulfonyl fluoride, 2 Amol/L pepstatin A, 2 Amol/L
leupeptin; all from Sigma). Cell debris were sedimented and discarded,
and protein concentration was measured by Lowry assay with a DC
Protein Assay kit (Bio-Rad, Hercules, CA). Proteins were prepared and
loaded (7.5 Ag/well) on 10% SDS-polyacrylamide gel in a Mini-PROTEAN
3 system (Bio-Rad) according to the instructions of the manufacturer.
Proteins were transferred to Hybond enhanced chemiluminescence (ECL)
membranes (Amersham Pharmacia Biotech, Buckinghamshire, United
Kingdom) and revealed by incubation with a goat gp100-specific antibody
(1:200; K-18; Santa Cruz, Santa Cruz, CA) or a mouse actin-specific
antibody (1:4,000; Chemicon, Temecula, CA) for 1 hour. Membranes were
washed and reincubated for 1 hour with secondary peroxidase-conjugated
antibodies, chicken anti-goat (1:10,000) or goat anti-mouse (1:40,000; both
from Chemicon), before detection with ECL Plus Western blotting
(Amersham Pharmacia Biotech).
Confocal microscopy. Cells were plated at 3  105 per well on poly-
D-lysine (Sigma)–treated coverslips in 12-well plates the day before
transfection (when necessary) and cultured for an additional 24 hours.
Before intracellular staining, the cells were washed once with PBS
(Invitrogen and Wisent) containing 0.5% bovine serum albumin (BSA;
Sigma), fixed, and permeabilized with BD Cytofix/Cytoperm (BD Bio-
sciences, Mississauga, ON) directly on coverslips for 20 minutes and washed
twice with BD Perm/Wash Solution (BD Biosciences).
Permeabilized cells were stained with a gp100-specific antibody (NK-1;
Bio-Design, Saco, ME), a LAMP-1-specific antibody (anti-CD107a; BD
Biosciences), or a pan-MHC Class II (HLA-DR, P, Q)–specific antibody
(TU¨39; BD Biosciences). After 30 minutes of incubation with the first
antibody, the cells were washed and reincubated for 30 minutes with
isotype-specific secondary antibodies coupled with Alexa Fluor-488 (green),
Alexa Fluor-568 (red), or Alexa Fluor-647 (blue; all from Molecular Probes,
Eugene, OR). The cells were then washed and the coverslips were mounted
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on microscope slides using Geltol (Immunon, Pittsburgh, PA). After
overnight incubation at 4jC, the coverslips were sealed with nail polish.
The cells were observed under a Leica TCS-SP1 confocal microscope
(Leica Microsystems, Mannheim, Germany) fitted with a 100 oil
immersion objective, analyzed by Leica Confocal Software, and processed
by Adobe Photoshop 7.0 (Adobe Systems, Inc., San Jose, CA).
Cell surface analyzed by flow cytometry. 293T cells were cotransfected
by plasmids coding for GFP and gp100 mutants. Preliminary experiments
in transient transfection by our group confirmed that the same cells were
cotransfected with two different plasmids, gp100 and GFP, for instance
(data not shown). Twenty-four hours later, the cells were harvested
with trypsin, distributed at >1  105 per tube in 5 mL polystyrene round-
bottomed tubes, and washed with PBS containing 0.5% BSA. For intra-
cellular staining, the cells were fixed and permeabilized with BD Cytofix/
Cytoperm for 20 minutes, then washed twice with BD Perm/Wash Solution
(both from BD Biosciences).
Intracellular and cell-surface staining were done using a gp100-specific
antibody (NK-1) or an isotype-matched control (IgG2b; BD Biosciences).
After 30 minutes of incubation, the cells were washed and reincubated
for 30 minutes with a phycoerythrin-conjugated isotype-specific secondary
antibody (anti-mouse-R-PE; Molecular Probes). The cells were finally
analyzed by flow cytometry on a Fluorescence-Activated Cell Sorter Calibur
(Becton Dickinson, Mississauga, ON). Only GFP-positive cells, which were
also positive for gp100, were analyzed by WinMDI 2.8 software. Gp100 cell-
surface expression was compared with total expression in permeabilized
cells.
Results
Exogenous and endogenous gp100 can be presented by MHC
class II molecules. We have previously reported the generation of
a CD4+ T-cell clone specific for an HLA-DRh1*0701 epitope from
gp100 (gp100170-190) using retrovirally transduced dendritic cells
(23). With this CD4+ T-cell clone, classic MHC class II–mediated
presentation of exogenous gp100 was first controlled. CD40-
stimulated B lymphocytes (CD40-B) served as a source of APC
(26). As expected, HLA-DRh1*0701+ APC pulsed with recombinant
gp100, but not the DRh1*0701 APC, were recognized by the CD4+
T-cell clone (Fig. 1A). APC pulsed with different amounts of gp100
peptide, corresponding to the DRh1*0701 epitope (gp100170-190),
were effectively recognized in a dose-dependent manner but
DRh1*0701+ APC pulsed with either a different recombinant
protein or a known DRh1*0701-binding peptide derived from the
immunoglobulin n light chain (Ign188202) were not recognized.
Figure 1. MHC class II–restricted presentation of endogenous and exogenous gp100. A, HLA-DRh1*0701+- or 0701-stimulated B lymphocytes (CD40-B) were
pulsed with recombinant gp100 (gp100r ), NY-ESO-1 (NY-ESO-1r ), different amounts of gp100170-190 peptide, or a DRh1*0701-binding control peptide (Ign188-202).
A gp100-specific CD4+ T-cell clone was cocultured with these target cells. B, an HLA-DRh1*0701+ gp100-deficient melanoma cell line (melFB) was retrovirally
transduced using genes encoding gp100 or GFP. 293T cells expressing HLA-DRh1*0701 or DRh1*0401 (DR7 or DR4) were cotransfected with plasmids coding for
gp100 or GFP and HLA-A*0201 or A*0101 (A2 or A1). Gp100-specific CD4+ and CD8+ T-cell clones were cocultured with these target cells. C, melanoma cell
lines expressing or not gp100, MHC class II molecules, or HLA-DRh1*0701 (DR7 ) were cocultured with a gp100-specific CD4+ T-cell clone. D, HLA-DRh1*0701+-
stimulated B lymphocytes (CD40-B) pulsed with recombinant gp100 (gp100r), HLA-DRh1*0701+ gp100-deficient melanoma cell line (MelFB) expressing gp100 or GFP,
gp100-transfected 293T cells expressing HLA-DRh1*0701, DRh1*0401, or HLA-A*0201 (DR7, DR4 , or A2), and melanoma cell lines expressing or not gp100 or
HLA-A*0201 (HLA-A2 ) were treated with 100 Amol/L chloroquine (CHL ) or left untreated (NT) as described in Materials and Methods. Gp100-specific CD4+ and CD8+
T-cell clones were cocultured with these target cells. A to D, supernatants were harvested after 20 hours of coculture and IFN-g secretion was determined
by ELISA. Representative of z5 independent experiments.
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We next deployed the same gp100-specific CD4+ T-cell clone to
evaluate MHC class II–mediated presentation from endogenously
expressed gp100. HLA-DRh1*0701+ melanoma cells (MelFB),
immunoselected for the absence of gp100, and 293T cells were
engineered to express gp100 or GFP. As expected, only cells
expressing gp100 and HLA-DRh1*0701 were recognized (Fig. 1B).
293T cells expressing a control gene (GFP) or a different MHC class
II molecule (HLA-DRh1*0401) failed to promote IFN-g secretion
from the CD4+ T-cell clone. In all cases, gp100 expression and class
I presentation were controlled by cotransfection of an HLA-A*0201
expression plasmid and recognition was monitored by a CD8+ T-
cell clone specific to an HLA-A*0201 gp100 epitope (gp100209-217;
ref. 25). We have previously confirmed that the amount of IFN-g
secretion by gp100-specific CD4+ (23) or CD8+ T-cell clones
correlated with the density of the peptide loaded on APC (data
not shown).
In addition, melanoma cells expressing gp100 and the class II
transactivator (CIITA), up-regulating invariant chain (Ii), HLA-DM,
and HLA-DR molecules, were recognized by the CD4+ T-cell clone
(624mel-CIITA, Fig. 1C), but not wild-type CIITA cells not expres-
sing HLA class II molecules. Melanoma cells naturally expressing
HLA class II molecules DRh1*0701 and gp100 (1087mel) were
recognized by the CD4+ T-cell clone. Other melanoma cells expres-
sing HLA class II molecules but not DRh1*0701 (1300mel) were not
recognized, confirming HLA-DRh1*0701-restricted presentation.
Finally, we evaluated if intracellular antigen processing was
required for MHC class II presentation of endogenously expressed
gp100. To do so, we treated target cells with chloroquine, which
inhibits the processing of exogenous antigen and MHC class II
presentation by neutralizing the pH of endosomes. As shown in
Fig. 1D (left), chloroquine treatment resulted in inhibition of
MHC class II presentation of exogenous gp100 by HLA-DRh1*0701+
APC pulsed with recombinant gp100 and endogenous gp100
expressed by the melanoma cell line or 293T cells expressing
HLA-DRh1*0701, indicating that intracellular processing was
required for MHC class II presentation. This inhibition was not
caused by chloroquine toxicity because similar treatments of tumor
cell lines did not inhibit MHC class I presentation of endogenous
gp100 (Fig. 1D, right) as expected.
Importantly, data revealed that gp100 can be presented by MHC
class II from either classic exogenous or endogenous pathways,
suggesting protein mobilization to the endosomal compartment
and MIIC.
Gp100 localizes to LAMP-1+ endosomal vesicles. Gp100
localization experiments were carried out with laser scanning
confocal microscopy. As shown in Fig. 2, gp100 seems to be
localized in intracellular vesicles in both melanoma and trans-
fected 293T cells (labeling in green). Double staining was done with
anti-LAMP-1, a membrane glycoprotein enriched in the lysosomal
membrane and found in endosomes/lysosomes and MIIC (30, 31).
Double staining revealed that several gp100+ vesicles were also
positive for LAMP-1 (in red), suggesting colocalization in endo-
somal compartments (yellow vesicles indicated by white arrows).
This experiment underscores the importance of the gp100
trafficking to endosomal compartments, which could be linked to
its MHC class II presentation.
Mapping of endosomal targeting sequences essential for
MHC class II presentation. Endosomal/melanosomal targeting
motifs could be involved in gp100 mobilization to MIIC and
optimize MHC class II–mediated presentation. We hypothesized
that the putative NH2-terminal signal sequence and the last 70
residues (Fig. 3C), which contain a transmembrane domain, a
tyrosine residue, and a putative dileucine motif, could be important
for gp100 trafficking to endosomal compartments. We prepared
different deletions in the gp100 sequence to map potential
sequences important for endosomal homing and MHC class II
presentation. Plasmids encoding gp100 mutants and HLA-A*0201
were cotransfected in 293T cells expressing HLA-DRh1*0701.
MHC class I presentation was monitored with a CD8+ T-cell clone
specific to an HLA-A*0201 epitope from gp100 (gp100209-217).
MHC class II presentation was evaluated with a CD4+ T-cell clone
specific to an HLA-DRh1*0701 epitope from gp100 (gp100170-190).
The different versions of deleted gp100 are represented in
Fig. 3A (left). Importantly, both MHC class I and class II epitopes
remained intact; only the last 70 residues were modified, which
is >350 amino acids downstream of the epitopes. As expected, on
the basis of IFN-g secretion, gp100- and HLA-A*0201-transfected
293-DRh1*0701+ cells were recognized by both CD4+ and CD8+
Figure 2. Colocalization of gp100 and
LAMP-1. 293T cells transfected with
plasmids coding for gp100 or tyrosinase
and a melanoma cell line expressing gp100
(MelFB-gp100) were permeabilized and
double stained with an anti-gp100 coupled
with Alexa Fluor-488 (green ) and an
anti-LAMP-1 coupled with Alexa Fluor-568
(red). The cells were analyzed by laser
scanning confocal microscopy. Yellow
vesicles, in merged images, revealed the
colocalization of gp100 and LAMP-1 (white
arrows ). Representative of three
independent experiments.
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T-cell clones whereas gp100- and HLA-A*0101-transfected 293-
DRh1*0701+ cells failed to be recognized by the CD8+ T-cell clone.
In addition, gp100- and HLA-A*0201-transfected 293-DRh1*0401+
cells failed to be recognized by the CD4+ T-cell clone. Although
MHC class I–mediated presentation was similar for all gp100
mutants (Fig. 3A), deletions in the COOH terminus resulted
in decreased MHC class II–restricted presentation. More specifi-
cally, deletion of the last 70 residues (gp100-NoTM) or internal
deletion of the transmembrane domain (gp100-DTM) reduced
MHC class II presentation to <10% of wild-type gp100, suggesting
an important role for the transmembrane domain. However,
as shown by the MHC class II/class I presentation ratio (Fig. 3B),
MHC class II presentation was not affected by substitution of
the transmembrane domain by the one from CD8 (gp100-CD8).
Interestingly, deletion of the putative dileucine motif (gp100-DLL),
a motif previously described as being important for protein
trafficking to endosomes (32–35), minimally diminished MHC
class II presentation, as illustrated by the MHC class II/class I
presentation ratio (Fig. 3B). Further deletion in the COOH-terminal
sequence downstream of the transmembrane domain (gp100-TM)
resulted in 45% IFN-g secretion by the CD4+ T-cell clone when
compared with the full-length sequence (Fig. 3A).
Interestingly, deletion of a sequence of 12 residues, including a
tyrosine and 3 consecutive arginines, located immediately after the
transmembrane domain (gp100-DYV), had minimal effect on MHC
class II presentation (Fig. 3A). However, this deletion combined
with CD8 transmembrane substitution (gp100-DYVCD8) abrogated
MHC class II presentation, which was revealed by the MHC class II/
class I presentation ratio (Fig. 3B). Finally, as expected, deletion
of the NH2-terminal signal sequence (gp100-DSS) resulted in a
marked decrease in MHC class II presentation with no change in
MHC class I presentation compared with wild-type gp100 (Fig. 3A).
These data suggested a similar expression for all mutants
considering that MHC class I–mediated presentation was
equivalent (Fig. 3A). A comparable expression level was further
confirmed by analysis of gp100 expression by Western blotting
(Fig. 3D). The expression level of gp100-DSS could not be evaluated
because the epitope recognized by the antibody was located in the
NH2 terminus.
Clearly, the data showed that the last 70 residues, including the
transmembrane domain and the NH2-terminal signal sequence, are
critical for gp100 MHC class II–mediated presentation. Interest-
ingly, multiple elements within these sequences seemed to be
involved in this process.
Gp100 surface expression correlates with MHC class II
presentation. Gp100 can possibly reach relevant endosomal
compartments by two pathways for proper processing and MHC
class II loading: (a) directly from the Golgi and (b) by transiting
to the cell surface with internalization. Interestingly, gp100
modification resulting in decreased MHC class II presentation
Figure 3. Mapping of gp100-derived
targeting sequences essential for MHC
class II presentation. A, plasmids encoding
gp100 mutants and HLA-A*0201 or A*0101
were cotransfected in 293T cells
expressing HLA-DRh1*0701 or
DRh1*0401. Gp100-specific CD4+ and
CD8+ T-cell clones were cocultured with
transfected cells and peptide presentation
was evaluated on the basis of IFN-g
secretion as determined by ELISA. Data
from gp100 mutants are presented as a
percentage of IFN-g secretion compared
with wild-type gp100, normalized to 100%.
Average of 10 independent experiments.
B, data from (A) are presented as a class
II/class I antigen presentation efficiency
ratio. C, amino acid sequences of the
transmembrane domain from CD8, the
transmembrane domain, and the COOH
terminus of gp100. D, gp100 expression
levels were revealed by Western blot
analysis with a gp100-specific antibody.
*, the epitope recognized by this antibody is
located in the NH2 terminus; consequently,
the expression level of gp100-DSS could
not be evaluated. E, gp100 cell-surface
expression was evaluated by flow
cytometry (Cell-surface expression). Total
gp100 expression was also evaluated by
permeabilizing transfected cells before
staining (Total gp100 ). Gp100 cell-surface
expression from all gp100 mutants is
summarized in (B ). Representative of six
independent experiments.
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was not caused by endoplasmic reticulum/Golgi retention because
endoglycosidase H sensitivity patterns were similar for all gp100
mutants (data not shown). Thus, to address the possibility of tran-
sition to the cell surface, we evaluated gp100 cell-surface expression
by flow cytometry and compared it with total expression in per-
meabilized cells (Fig. 3E). All gated transfected cells were gp100+
and surface expression was detected in 59% of these cells. The
assessment of gp100 cell-surface expression determinates for all
mutants is summarized in Fig. 3B . Interestingly, all cells transfected
with plasmid encoding gp100-DLL mobilized gp100 at the cell
surface (Fig. 3E). In contrast, gp100-NoTM, gp100-DTM, gp100-DSS,
and gp100-DYVCD8 failed to mobilize to the cell surface.
Consequently, as illustrated in Fig. 3B , there was a direct correlation
between gp100 cell-surface expression and the MHC class II/class I
presentation ratio. These results suggest that gp100 could transit to
the cell surface to gain access to relevant endosomal compartments
and MIIC.
Gp100 cell-surface expression may be due to overexpression in
cells without melanosomes. Consequently, we also evaluated gp100
cell-surface and total expression from eight different melanoma cell
lines. Gp100 expression was detected in six of seven melanoma
cell lines tested (excluding MelFB; Fig. 4) and gp100 cell-surface
expression was observed in three of these six melanoma cell lines.
We also noted gp100 cell-surface expression in a gp100 melanoma
cell line (MelFB) engineered to express gp100. Surface expression
may have clinical implications and needs to be further investigated.
Endosomal localization of gp100 mutants presented by
MHC class II. Characterization of the different versions of deleted
gp100 was completed by gp100 localization experiments with laser
scanning confocal microscopy of transfected 293T cells stained for
gp100 and LAMP-1. As expected, gp100 mutants, presented by
MHC class II, were located in intracellular vesicles colocalizing
with LAMP-1 (yellow vesicles), similar to wild-type gp100 (Fig. 5A).
In contrast, the other gp100 mutants showed no specific vesicular
localization and no colocalization with LAMP-1, showing the
importance of these deleted sequences in gp100 trafficking.
Interestingly, we found higher gp100 cell-surface expression in
gp100-DLL-transfected cells than in wild-type gp100-transfected
cells (green fluorescence in cell outline), confirming the gp100-DLL
cell-surface expression already noted by flow cytometry (Fig. 3E).
To further confirm that LAMP-1+ endosomes colocalizing with
gp100 were MIIC, we stained gp100-transfected 293T cells and
melanoma cells with an anti-gp100, an anti-LAMP-1, and an
anti-HLA-DR, and laser scanning confocal microscopy was done.
As shown in Fig. 5B , LAMP-1+ vesicles containing gp100 (yellow
vesicles in the left image) were also positive for HLA-DR (white
vesicles in the central image), indicating that they were MIIC.
LAMP-1+/HLA-DR vesicles in MelFB may represent melanosomes.
These latter experiments confirmed that the putative NH2-
terminal signal sequence and the last 70 residues are essential for
gp100 mobilization in MIIC.
Gp100 targeting sequences mobilize GFP to endosomes and
allow the presentation of minimal class II and class I epitopes.
Gp100 targeting sequences were cloned in fusion with GFP,
transfected in 293T cells engineered to express HLA class II
and accessory molecules, and laser scanning confocal microscopy
Figure 4. Gp100 cell-surface expression in melanoma cell lines. Gp100 cell-surface expression from different melanoma cell lines was evaluated by flow cytometry
(Cell surface ). Total gp100 expression was also evaluated, by permeabilizing cells before staining (Total ). Representative of three independent experiments.
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was undertaken. As presented in Fig. 6A , wild-type GFP showed no
particular mobilization. However, GFP in fusion with the putative
signal sequence and the last 70 residues from gp100 (gp100/GFP)
colocalized with LAMP-1 (yellow vesicles indicated by white
arrows). This confirms the importance of these sequences for
protein localization in endosomal compartments and MIIC.
To link endosomal localization to MHC class II–mediated
presentation, a short sequence from gp100, corresponding to
minimal class II and class I epitopes, was inserted after GFP within
the last-mentioned construct. Plasmids encoding this chimeric
protein (gp/GFP+epit) and HLA-A*0201 or A*0101 were cotrans-
fected in 293T cells expressing HLA-DRh1*0701 or DRh1*0401.
GFP expression was confirmed by flow cytometry and vesicular
mobilization was studied by fluorescence microscopy (data not
shown). As presented in Fig. 6B , 293-DRh1*0701 cells transfected by
plasmids encoding gp/GFP+epit or wild-type gp100 were recognized
by the CD4+ T-cell clone. As expected, 293-DRh1*0401 failed to
stimulate the CD4+ T-cell clone. Interestingly, gp/GFP+epit and
full-length gp100 were efficiently recognized by the CD8+ T-cell clone
and the negative control, HLA-A*0101-transfected 293T cells, failed
to be recognized. Presentation of gp100-MHC class II epitope was
further confirmed in melanoma (MelFB; Fig. 6C) and APC (CD40-B).
The latter experiments confirm the importance of these
sequences for mobilization to endosomes and for MHC class II–
mediated presentation of endogenous gp100.
Discussion
MHC class II antigenic presentation plays a critical role in
antitumor immunity. Interestingly, specific endogenous proteins
can reach MIIC and get processed for MHC class II presentation,
similarly to exogenous proteins. Previous data suggested that
endogenous gp100 can be presented by MHC class II molecules and
stimulates specific CD4+ T lymphocytes (23, 24). Consequently, we
Figure 5. Endosomal localization of gp100
mutant. A, 293T cells transfected with plasmid
coding for gp100 or gp100 mutants were
permeabilized and double stained with an
anti-gp100 coupled with Alexa Fluor-488 (green )
and an anti-LAMP-1 coupled with Alexa Fluor-568
(red). The cells were analyzed by laser scanning
confocal microscopy. Yellow vesicles, in mutants
presented by MHC class II, revealed colocalization
of gp100 and LAMP-1. Representative of two
independent experiments. B, gp100-transfected
293T cells and a melanoma cell line expressing
gp100 (MelFB-gp100) were permeabilized and
stained with an anti-gp100 coupled with Alexa
Fluor-488 (green ), an anti-HLA-DR coupled with
Alexa Fluor-568 (red ), and an anti-LAMP-1
coupled with Alexa Fluor-647 (blue ). The cells were
analyzed by laser scanning confocal
microscopy. White vesicles, in the central image,
revealed colocalization of gp100, LAMP-1, and
MHC class II molecule HLA-DR. Representative of
two independent experiments.
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wanted to further characterize MHC class II–mediated presenta-
tion of endogenous proteins and endosomal/MIIC internal
trafficking leading to MHC class II presentation. We confirmed
that exogenous and endogenous gp100 can be presented by MHC
class II. We also showed that gp100 expressed endogenously can
reach LAMP-1+/HLA-DR+ endosomal/MIIC, of which processing
correlates with presentation by MHC class II. Therefore, we
expected to define sequences within gp100 involved in these
processes. Our results showed that the putative NH2-terminal
signal sequence and the last 70 residues in the COOH terminus are
essential for endosomal localization and MHC class II–mediated
presentation of endogenous gp100. Moreover, we showed that
gp100 cell-surface expression correlates with MHC class II
presentation, suggesting gp100 transition to the cell surface before
internalization to relevant endosomal/MIIC.
Mobilization of endogenous proteins to endosomal/MIIC and
processing through the MHC class II pathway has already
been evoked, especially in melanoma. Some melanosomal pro-
teins might contain epitopes recognized by CD4+ T lymphocytes.
Topalian et al. (36) had previously found tyrosinase-specific CD4+ T
cells from populations of tumor-infiltrating lymphocytes cultured
from a metastatic melanoma lesion. Other groups had also isolated
tyrosinase-specific CD4+ T lymphocytes from peripheral blood of
melanoma patients (37, 38). It could be suggested that tyrosinase
and probably other melanosome membrane proteins, such as
gp100, have the capacity to reach MHC class II molecules
Figure 6. Endosomal mobilization of GFP and presentation of minimal MHC class II and class I epitopes using gp100 targeting sequences. A, schematic
representation of GFP modified with gp100 targeting sequences (gp100/GFP). 293T cells were transfected with plasmids coding for GFP, gp100, or gp100/GFP. The
cells were permeabilized, stained with an anti-LAMP-1 coupled with Alexa Fluor-568 (red), and analyzed by laser scanning confocal microscopy. Yellow vesicles, in
merged image, revealed colocalization of gp100/GFP and LAMP-1 (white arrows). Representative of five independent experiments. B, schematic representation of
GFP modified with gp100 targeting sequences and minimal MHC class II and class I gp100 epitopes (gp/GFP+epit ). Plasmids encoding gp100 or gp/GFP+epit were
transfected in 293T cells expressing HLA-DRh1*0701 or DRh1*0401, and a gp100-specific CD4+ T-cell clone was cocultured with these transfected cells (left).
Plasmids encoding gp100 or gp/GFP+epit and HLA-A*0201 or A*0101 were cotransfected in 293T cells, and a gp100-specific CD8+ T-cell clone was cocultured with
these transfected cells (right). Supernatants were harvested after 20-hour coculture and IFN-g secretion was measured by ELISA. Data are presented as a percentage
of IFN-g secretion compared with gp100, normalized to 100%. Average of two independent experiments. C, a melanoma cell line (MelFB) and HLA-DRh1*0701+- or
*0701-stimulated B lymphocytes (CD40-B) were electroporated with plasmids coding for gp100, gp/GFP+epit, or tyrosinase, and a gp100-specific CD4+ T-cell clone
was cocultured with these target cells. Representative of two independent experiments.
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transported to endosomal/MIIC. Possibly, melanosomes, endo-
somes/lysosomes, and MIIC may be compartments with very
similar characteristics (39, 40). Because gp100 is known to reach
melanosomal compartments via an intracellular pathway (41), it
can also possibly reach endosomal/MIIC by a similar pathway.
Two major pathways have been defined by which proteins enter
endosomal/MIIC to be processed for MHC class II–restricted
presentation and recognition by CD4+ T lymphocytes. The tradi-
tional pathway involves the endocytosis of exogenous proteins by
APC. In contrast, the second pathway implicates the processing of
endogenously synthesized membrane proteins (42). These mem-
brane proteins are believed to enter endosomal compartments by
internalization from the cell surface. As we observed a direct
correlation between gp100 cell-surface expression and MHC class
II–mediated presentation (Fig. 3B), it is possible that gp100 also
reached endosomal/MIIC by internalization from the cell surface.
Considering previous studies showing that melanosomal glyco-
proteins were mobilized to melanosomes by a dileucine-based
sorting motif (32), we originally predicted that removal of the
putative gp100-dileucine motif would impair endosomal/MIIC
mobilization and MHC class II presentation. Surprisingly, removal
of the gp100 putative dileucine motif (gp100-DLL) unchanged
mobilization to LAMP-1+ endosomes (Fig. 5A) and presentation by
MHC class II (Fig. 3A). It is plausible that this putative dileucine
motif is not functional even if it fits with the accepted consensus
sequence. Actually, functional dileucine motifs from gp75 (43) and
tyrosinase (33, 34) are structurally surrounded by basic residues, an
acidic spacer, and tyrosine residues, which is not the case for gp100.
However, the gp100 transmembrane domain is clearly important
for endosomal/MIIC mobilization and MHC class II–mediated
presentation. We showed that substitution of the transmembrane
domain by the one from CD8 did not affect gp100 MHC class II–
mediated presentation (Fig. 3A), indicating that the presence
of a transmembrane domain with all other sequences could be
sufficient to mediate endosomal/MIIC mobilization of gp100.
Interestingly, deletion of a sequence, including a tyrosine residue
and three consecutive arginine residues, located immediately after
the transmembrane domain and associated with CD8 transmem-
brane substitution, negatively affected MHC class II presentation
whereas deletion of this sequence alone had no effect compared
with wild-type gp100 (Fig. 3A). This could possibly be caused by
an inappropriate folding of the protein within the membrane in
the gp100-DYVCD8 construct. However, it could also suggest the
involvement of important residues in the gp100 Y to V sequence
(residues 616-627) that may have a role with the gp100-specific
transmembrane domain for endogenous MHC class II presentation,
but both are not absolutely required. Interestingly, other membrane
glycoproteins, such as LAMP-1 or other lysosomal proteins, contain
a lysosomal-trafficking tyrosine residue in a specific position within
the cytoplasmic tail (44, 45).
Specifically, the lysosomal targeting signal formed the pattern
Y-X-X-hydrophobic residue (46). In the gp100 sequence, the tyrosine
residue is followed by three consecutive arginine residues before a
leucine, a hydrophobic residue (Y-R-R-R-L). Three arginine residues
have already been identified as an endoplasmic reticulum retention
signal (RXR; refs. 47, 48), known to play an important role
in trafficking of many membrane proteins to the cell surface (49).
Here, we observed that deletion of this motif did not affect gp100
cell-surface trafficking (Fig. 3B). However, MHC class II presenta-
tion was abrogated when this deletion was associated with CD8
transmembrane substitution (Fig. 3A).
Interestingly, these findings suggested that more than one
sequence have a related role in gp100 MIIC trafficking. Moreover,
we confirmed that there are essential sequences present within the
gp100 putative NH2-terminal signal sequence and the last 70
residues in the COOH terminus for endosomal/MIIC localization
and MHC class II–mediated presentation of endogenous gp100.
To complete our study, we employed these gp100 targeting
sequences to mobilize GFP, as a model endogenous protein, to
endosomal compartments (Fig. 6A). In addition, we showed that
these targeting sequences allow MHC class II and class I
presentation of endogenous epitopes linked to GFP in 293T cells,
melanoma, and APC (Fig. 6B and C). Consequently, we believe that
these sequences could be exploited as a tool in vivo to optimize
CD4+ and CD8+ T-cell responses against tumor- and viral-associated
antigens. Specifically, MIIC-targeting sequences could be included
in expression cassettes for DNA vaccines or for improved expression
in APC and optimized MHC class II presentation without apparent
negative effect on MHC class I presentation. Thus, these targeting
sequences could also be exploited as an in vitro tool to characterize
new MHC class II epitopes and promote the stimulation of both
CD4+ and CD8+ T cells.
Acknowledgments
Received 7/19/2005; revised 11/15/2005; accepted 12/22/2005.
Grant support: Canadian Institutes of Health Research, La Fondation du Centre
Hospitalier de l’Universite´ de Montre´al, scholarship from Fond pour la recherche en
sante´ du Que´bec (R. Lapointe), and studentship from the Canderel fund of the Institut
du Cancer de Montre´al (S. Lepage).
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Ovid Da Silva from the ‘‘Bureau d’aide a` la recherche’’ ( from Centre
Hospitalier de l’Universite´ de Montre´al) for text editing, Dr. Jacques Thibodeau for
critical review of the manuscript and helpful discussions, and Diane Beauseigle for
technical support.
References
1. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C,
Pardoll D, Levitsky H. The central role of CD4(+) T cells
in the antitumor immune response. J Exp Med 1998;188:
2357–68.
2. Surman DR, Dudley ME, Overwijk WW, Restifo NP.
Cutting edge: CD4+ T cell control of CD8+ T cell
reactivity to a model tumor antigen. J Immunol 2000;
164:562–5.
3. Corthay A, Skovseth DK, Lundin KU, et al. Primary
antitumor immune response mediated by CD4(+) T
cells. Immunity 2005;22:371–83.
4. Phan GQ, Touloukian CE, Yang JC, et al. Immunization
of patients with metastatic melanoma using both class
I- and class II-restricted peptides from melanoma-
associated antigens. J Immunother 2003;26:349–56.
5. Wong R, Lau R, Chang J, et al. Immune responses to a
class II helper peptide epitope in patients with stage III/
IV resected melanoma. Clin Cancer Res 2004;10:5004–13.
6. Toes REM, Ossendorp F, Offringa R, Melief CJM. CD4 T
cells and their role in antitumor immune responses.
J Exp Med 1999;189:753–6.
7. Wang RF. The role of MHC class II-restricted tumor
antigens and CD4+ T cells in antitumor immunity.
Trends Immunol 2001;22:269–76.
8. Janssen EM, Lemmens EE, Wolfe T, Christen U, von
Herrath MG, Schoenberger SP. CD4(+) T cells are
required for secondary expansion and memory in
CD8(+) T lymphocytes. Nature 2003;421:852–6.
9. Shedlock DJ, Shen H. Requirement for CD4 T cell help
in generating functional CD8 T cell memory. Science
2003;300:337–9.
10. Velders MP, Markiewicz MA, Eiben GL, Kast WM.
CD4(+) T cell matters in tumor immunity. Int Rev
Immunol 2003;22:113–40.
11. Gerloni M, Zanetti M. CD4 T cells in tumor
immunity. Springer Semin Immunopathol 2005;27:
37–48.
MHC Class II–Mediated Presentation of Endogenous gp100
www.aacrjournals.org 2431 Cancer Res 2006; 66: (4). February 15, 2006
12. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA.
CD4+CD25(high) regulatory cells in human peripheral
blood. J Immunol 2001;167:1245–53.
13. Javia LR, Rosenberg SA. CD4(+)CD25(+) suppressor
lymphocytes in the circulation of patients immunized
against melanoma antigens. J Immunother 2003;26:
85–93.
14. Wang HY, Lee DA, Peng GY, et al. Tumor-specific
human CD4(+) regulatory T cells and their ligands:
implications for immunotherapy. Immunity 2004;20:
107–18.
15. Piccirillo CA, Shevach EM. Cutting edge: Control of
CD8(+) T cell activation by CD4(+)CD25(+) immunoreg-
ulatory cells. J Immunol 2001;167:1137–40.
16. Murakami M, Sakamoto A, Bender J, Kappler J,
Marrack P. CD25+CD4+ T cells contribute to the control
of memory CD8+ T cells. Proc Natl Acad Sci U S A 2002;
99:8832–7.
17. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O,
Barbosa TC, Cumano A, Bandeira A. CD25(+) CD4(+) T
cells regulate the expansion of peripheral CD4 T cells
through the production of IL-10. J Immunol 2001;166:
3008–18.
18. Almeida ARM, Legrand N, Papiernik M, Freitas AA.
Homeostasis of peripheral CD4(+) T cells: IL-2Ra and IL-
2 shape a population of regulatory cells that controls
CD4(+) T cell numbers. J Immunol 2002;169:4850–60.
19. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR,
Serrano S, Garrido F. Phenotypic and genetic-analysis of
HLA class-I and HLA-DR antigen expression on human
melanomas. Exp Clin Immunogenet 1988;5:203–12.
20. Bernsen MR, Hakansson L, Gustafsson B, et al. On
the biological relevance of MHC class II and B7
expression by tumour cells in melanoma metastases.
Br J Cancer 2003;88:424–31.
21. Brocker EB, Suter L, Sorg C. HLA-DR antigen
expression in primary melanomas of the skin. J Invest
Dermatol 1984;82:244–7.
22. Sachse M, Ramm G, Strous G, Klumperman J.
Endosomes: multipurpose designs for integrating house-
keeping and specialized tasks. Histochem. Cell Biol
2002;117:91–104.
23. Lapointe R, Royal RE, Reeves ME, Altomare I,
Robbins PF, Hwu P. Retrovirally-transduced human
dendritic cells can generate T cells recognizing multiple
MHC class I and class II epitopes from the melanoma
antigen gp100. J Immunol 2001;167:4758–64.
24. Lapointe R, Thibodeau J, Hwu P. Correspondence re
R. Lapointe et al., CD40-stimulated B lymphocytes
pulsed with tumor antigens are effective antigen-
presenting cells that can generate specific T cells.
(Cancer Res 2003;63:2836–43). Cancer Res 2004;64:
4056–7.
25. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA.
Antitumor immunization with a minimal peptide
epitope (G9–209–2M) leads to a functionally heteroge-
neous CTL response. J Immunother 1999;22:288–98.
26. Lapointe R, Bellemare-Pelletier A, Housseau F,
Thibodeau J, Hwu P. CD40-stimulated B lymphocytes
pulsed with tumor antigens are effective antigen-
presenting cells that can generate specific T cells.
Cancer Res 2003;63:2836–43.
27. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS,
Strominger JL. Specificity and promiscuity among
naturally processed peptides bound to HLA-DR alleles.
J Exp Med 1993;178:27–47.
28. Touloukian CE, Leitner WW, Topalian SL, et al.
Identification of a MHC class II-restricted human gp100
epitope using DR4-IE transgenic mice. J Immunol 2000;
164:3535–42.
29. Zeng G, Touloukian CE, Wang X, Restifo NP,
Rosenberg SA, Wang RF. Identification of CD4+ T cell
epitopes from NY-ESO-1 presented by HLA-DR mole-
cules. J Immunol 2000;165:1153–9.
30. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ.
Segregation of MHC class II molecules from MHC class I
molecules in the golgi complex for transport to
lysosomal compartments. Nature 1991;349:669–75.
31. Calafat J, Nijenhuis M, Janssen H, et al. Major
histocompatibility complex class-II molecules induce
the formation of endocytic MIIC-like structures. J Cell
Biol 1994;126:967–77.
32. Wang S, Bartido S, Yang G, et al. A role for a
melanosome transport signal in accessing the MHC
class II presentation pathway and in eliciting CD4+ T
cell responses. J Immunol 1999;163:5820–6.
33. Simmen T, Schmidt A, Hunziker W, Beermann F. The
tyrosinase tail mediates sorting to the lysosomal
compartment in MDCK cells via a di-leucine and a
tyrosine-based signal. J Cell Sci 1999;112:45–53.
34. Calvo PA, Frank DW, Bieler BM, Berson JF, Marks MS.
A cytoplasmic sequence in human tyrosinase defines a
second class of di-leucine-based sorting signals for late
endosomal and lysosomal delivery. J Biol Chem 1999;
274:12780–9.
35. Le Borgne R, Planque N, Martin P, Dewitte F,
Saule S, Hoflack B. The AP-3-dependent targeting of
the melanosomal glycoprotein QNR-71 requires a
di-leucine-based sorting signal. J Cell Sci 2001;114:
2831–41.
36. Topalian SL, Rivoltini L, Mancini M, et al. Human
CD4+ T cells specifically recognize a shared melanoma-
associated antigen encoded by the tyrosinase gene. Proc
Natl Acad Sci U S A 1994;91:9461–5.
37. Yee C, Gilbert MJ, Riddell SR, et al. Isolation of
tyrosinase-specific CD8(+) and CD4(+) T cell clones
from the peripheral blood of melanoma patients
following in vitro stimulation with recombinant vaccinia
virus. J Immunol 1996;157:4079–86.
38. Kobayashi H, Kokubo T, Sato K, et al. CD4(+) T cells
from peripheral blood of a melanoma patient recognize
peptides derived from nonmutated tyrosinase. Cancer
Res 1998;58:296–301.
39. Raposo G, Marks MS. The dark side of lysosome-
related organelles: Specialization of the endocytic
pathway for melanosome biogenesis. Traffic 2002;3:
237–48.
40. Zhou BK, Boissy RE, Pifko-Hirst S, Moran DJ, Orlow
SJ. Lysosome-associated membrane protein-1 (LAMP-1)
is the melanocyte vesicular membrane glycoprotein
band II. J Invest Dermatol 1993;100:110–4.
41. Berson JF, Harper DC, Tenza D, Raposo G, Marks MS.
Pmel17 initiates premelanosome morphogenesis within
multivesicular bodies. Mol Biol Cell 2001;12:3451–64.
42. Polydefkis M, Koenig S, Flexner C, et al. Anchor
sequence-dependent endogenous processing of human
immunodeficiency virus 1 envelope glycoprotein gp160
for CD4+ T cell recognition. J Exp Med 1990;171:875–87.
43. Vijayasaradhi S, Xu Y, Bouchard B, Houghton AN.
Intracellular sorting and targeting of melanosomal
membrane proteins: identification of signals for sorting
of the human brown locus protein, gp75. J Cell Biol 1995;
130:807–20.
44. Williams MA, Fukuda M. Accumulation of mem-
brane-glycoproteins in lysosomes requires a tyrosine
residue at a particular position in the cytoplasmic tail.
J Cell Biol 1990;111:955–66.
45. Peters C, Braun M, Weber B, et al. Targeting of a
lysosomal membrane-protein-A tyrosine-containing en-
docytosis signal in the cytoplasmic tail of lysosomal
acid-phosphatase is necessary and sufficient for target-
ing to lysosomes. EMBO J 1990;9:3497–506.
46. Guarnieri FG, Arterburn LM, Penno MB, Cha Y,
August JT. The motif Tyr-X-X-hydrophobic residue
mediates lysosomal membrane targeting of lysosome-
associated membrane protein-1. J Biol Chem 1993;268:
1941–6.
47. Schutze MP, Peterson PA, Jackson MR. An N-terminal
double-arginine motif maintains type-II membrane
proteins in the endoplasmic reticulum. EMBO J 1994;
13:1696–705.
48. Standley S, Roche KW, McCallum J, Sans N, Wenthold
RJ. PDZ domain suppression of an ER retention signal in
NMDA receptor NR1 splice variants. Neuron 2000;28:
887–98.
49. Xia H, Hornby ZD, Malenka RC. An ER retention
signal explains differences in surface expression of
NMDA and AMPA receptor subunits. Neuropharmacol-
ogy 2001;41:714–23.
Cancer Research
Cancer Res 2006; 66: (4). February 15, 2006 2432 www.aacrjournals.org
